Phase 1 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are older than 18 years at the time of signing the consent form
- People whose cancer-related physical functioning is rated at a 0 or 1 on a standard scale used by doctors (meaning able to carry out normal daily activities with little or no restriction)
- People who have been diagnosed with extensive stage small cell lung cancer confirmed through a tissue sample analysis
- People whose cancer has come back after receiving at least one prior cancer treatment given throughout the body (such as chemotherapy)
- People who have tumor tissue samples available — either stored from a previous biopsy or from a new biopsy
- People whose cancer can be measured on scans according to a standard set of measurement rules used in cancer research
- People whose blood counts and organ functions (such as liver and kidneys) are within acceptable levels as determined by the trial site
Who may not be able to join:
- People who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
- People who have a history of a significant autoimmune disease (a condition where the immune system attacks the body)
- People who test positive for HIV at the screening stage
- People who have active hepatitis B or hepatitis C infection
- People who have previously received certain targeted antibody treatments, specifically those directed at CD137, CD3, or DLL3 (confirm with trial site if unsure whether a past treatment falls into these categories)
- People who have received any cancer treatment — including hormone therapy or radiation — within the 21 days before the first dose of the study drug
- People who have previously experienced a severe (grade 4) immune-related side effect from certain immunotherapy drugs that target PD-L1, PD-1, or CTLA-4
- People who had to stop a prior immunotherapy drug due to a serious (grade 3) immune-related side effect, or who experienced such a side effect within 6 months before the first dose of the study drug
- People who received a live vaccine within the 4 weeks before the first dose of the study drug
- People who have a history of cancer that started in the brain or spinal cord, brain or spinal cord spread that is causing symptoms or requires treatment, or spread to the lining around the brain
- People who have a current or past significant brain or nervous system condition, such as stroke, epilepsy, inflammation of blood vessels in the brain, or a degenerative neurological disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sponsor Chugai Pharmaceutical Co.Ltd, clinical-trials@chugai-pharm.co.jp
Phone: only use Email
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
All part : Adverse events of ALPS12[safety and tolerability]; Dose Escalation part : Dose-limiting toxicities (DLTs) and PK profile of ALPS12[safety and tolerability]; Dose Escalation part : Immunogenicity of ALPS12; Expansion part : Preliminary anti-tumor activity of ALPS12 when administered at selected dose(s) based on tumor assessment in patients with extensive stage SCLC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.